Amneal Pharmaceuticals, Inc. (AMRX) — Fair Value Analysis
Base-case fair value (P50): $15.83 · Current price: $17.23 · Verdict: Fairly Valued
The Verdict on AMRX
Our Monte Carlo simulations indicate AMNEAL PHARMACEUTICALS INC CLASS A (AMRX) is Fairly Valued, with a median fair value (P50) of $15.83 against its current market price of $17.23. This assessment suggests the market largely aligns with our probabilistic valuation, presenting an -8.1% gap between the two figures. While some investors may seek greater implied upside, the current valuation reflects a balanced risk-reward profile based on our comprehensive analysis of thousands of forward-looking scenarios. The verdict of Fairly Valued at the $17.23 implies that AMRX is trading close to its intrinsic value.
How AMRX stacks up against Healthcare
AMRX’s 'average' quality tier, when evaluated against the broader Healthcare sector, provides crucial context to its Fairly Valued status. An average quality tier signifies that AMRX's operational and financial health metrics are in line with its sector peers, rather than standing out significantly at either end of the spectrum. This balanced profile supports the current $17.23 trading near our $15.83 fair value, as it suggests the company is neither exceptionally strong nor weak in comparison to others in Healthcare. The -8.1% gap also underscores this general alignment with market expectations.
What this means for investors
For investors considering AMRX at $17.23, the -8.1% gap to our $15.83 fair value indicates that immediate, significant mispricing opportunities are limited according to our Monte Carlo models. While the stock is currently Fairly Valued, understanding the full probability distribution of potential outcomes is key for informed decision-making. Investors should consider AMRX's 'average' quality tier as they evaluate its potential within the Healthcare sector. With FairCurve, you can track AMRX's fair value as new fundamentals are released and explore the full bear/bull distribution with a free account.
Frequently Asked Questions
Is AMRX overvalued or undervalued right now?
Based on our Monte Carlo simulations, AMRX has a median fair value of $15.83 compared to its current price of $17.23, leading to a 'Fairly Valued' verdict.
What is the bear case and bull case for AMRX?
Our comprehensive Monte Carlo simulations generate a full probability distribution, including specific bear (P10) and bull (P90) price targets, as well as the probability of upside. This detailed analysis is exclusively available when you sign up for a free FairCurve account.
How does FairCurve calculate AMRX's fair value?
FairCurve utilizes advanced Monte Carlo simulations to project AMRX's fair value across thousands of forward scenarios, incorporating various financial drivers to generate a robust valuation estimate.
How can I track AMRX's fair value as it changes?
Add AMRX to your free FairCurve watchlist to receive daily fair-value updates and instant re-valuations whenever new earnings or significant fundamental data are released.